Improvement of radioimmunotherapy using pretargeting

Area of Science:

• Nuclear medicine and oncology
• Development of targeted radiotherapies
• Molecular imaging and therapy

Background:

• Radioimmunotherapy (RIT) is effective for hematologic cancers but limited for solid tumors.
• Challenges in RIT for solid tumors include poor antibody penetration and normal tissue toxicity.
• Pretargeting techniques (pRIT) aim to overcome these limitations by separating antibody and radionuclide delivery.

Purpose of the Study:

• To review the technical and clinical aspects of pretargeted radioimmunotherapy (pRIT).
• To highlight advancements in pRIT strategies and molecular constructs.
• To discuss the future potential of pRIT in cancer treatment and imaging.

Main Methods:

• Decoupling monoclonal antibody (mAb) delivery from radionuclide delivery.
• Utilizing various binding strategies like avidin/streptavidin-biotin and bispecific antibodies.
• Employing new molecular constructs such as Dock and Lock technology.

Main Results:

• pRIT significantly improves the tumor-to-normal tissue ratio of radioactivity.
• Demonstrated survival benefit in medullary thyroid carcinoma.
• Reduced hematologic toxicity compared to conventional RIT.

Conclusions:

• Pretargeted radioimmunotherapy represents the next generation of RIT for solid malignancies.
• Advancements in pRIT offer improved tumor targeting and reduced systemic toxicity.
• pRIT holds significant promise for both cancer therapy and diagnostic imaging.